BioAro has announced its plans to launch PanOmiQ, a genomic analysis software that reportedly provides real-time decoding of genomic sequences. The Global launch is scheduled on May 9, 2024, during the Precision Medicine Expo at the Dubai World Trade Center.

PanOmiQ's capabilities include microbial community analysis (metagenomics), pharmacogenomics, and upcoming multi-omics analysis covering proteins, metabolites, and the transcriptome. This integrated approach potentially identifies biomarkers affected by lifestyle, medications, and environment, aiding personalized interventions for complex disorders like irritable bowel syndrome (IBS). PanOmiQ is claimed to be compatible with genetic file formats like FastQ and VCF and has access to over 20 databases, ensuring precision and detailed outcomes.

Canada-based BioAro is a biotechnology company that offers whole genome sequencing, microbiome testing, and software solutions. BioAro's healthcare software solutions include BioChain, which uses blockchain technology to store and share health data; PGAro for personalized medicine and pharmacogenomics; GMP for monitoring genetic changes and identifying mutations and diseases; and the BioEMR electronic medical record system to record and analyze patient data.